Navigation Links
shown in Medical Technology

NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection

EMERYVILLE, Calif., March 7 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY), a mid-stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective products for the treatment and prevention of a wide range of bacterial, fungal, and viral infe...

MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series

Eleven of eleven wounds healed in 6 weeks or less PRINCETON, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI ), a provider of advanced wound care products, announced today that its MEDIHONEY Dressings were the focus of a case series on eleven non-heal...

Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

CARLSBAD, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that OncoGenex Pharmaceuticals, Inc. provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm...

SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.

FRESNO, Calif., Oct. 29 /PRNewswire/ -- Cypress Systems, Inc., a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results -- that were announced yesterday -- used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine o...

Protein Shown to Play a Key Role in Normal Development of Nervous System

- Findings May Someday Inform Treatments for Spinal Cord, Other Nerve Injuries - PHILADELPHIA, Oct. 8 /PRNewswire-USNewswire/ -- A protein that enables nerve cells to communicate with each other plays a key role in controlling the developing nervous system. Research into how that protein hel...

Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months

BARCELONA, Spain, Sept. 2 /PRNewswire-FirstCall/ -- Final results from a 24-week study presented today at a major medical meeting in Barcelona suggest that investigational olanzapine long-acting injection (LAI) therapeutic doses showed a maintenance of treatment benefit for up to six months. A...

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date

Believed by experts to be important for cervical cancer prevention GRAZ, Austria, May 14 /PRNewswire-FirstCall/ -- New data from an extended follow-up study show that GlaxoSmithKline (NYSE: GSK ) cervical cancer candidate vaccine, CERVARIX(R) generates sustained high levels of neutralizing...

Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks

Single-Dose, Volunteer fMRI Study Completed and Reported Today Dosing in Four Week Higher Repeat Dose Study Completed HAMBURG, Germany and OXFORD, England, March 28 /PRNewswire-FirstCall/ -- Evotec (Frankfurt Stock Exchange: EVT) is pleased to announce the preliminary findings of ...

Divine Corporation's Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute

An Independent Study by the National Cancer Institute Revealed Divine No. 9 and Divine No. 8 to be Highly Effective in Inhibiting Viruses that Cause Cervical, Vaginal and Anal Cancers in vitro ORLANDO, Fla., Jan. 22 /PRNewswire/ -- Divine Corporation announced today an unprecedent...

SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients

Inhibition Was Sustained and Dose-Dependent in Sub-Analysis of Phase II TRA- PCI Trial ORLANDO, Fla., Nov. 7 /PRNewswire-FirstCall/ -- SCH 530348 (TRA), the novel investigational antiplatelet agent in development by Schering-Plough Corporation (NYSE: SGP ), was sho...

RediClinic Offers Affordable New Plan Clinically Shown to Double a Person's Chance to Stop Smoking

Retail Clinics Provide 12-week Plan to Help People Kick the Habit HOUSTON, Aug. 2 /PRNewswire/ -- RediClinic LLC announced today that it is offering an affordable new program to help people quit smoking. The four-step "Stop Smoking for Good(TM)" plan, available at RediClinics nationwide, in...

CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals

VIENNA, Va., May 01, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announces that CEL-1000 alone increased the immune response against hepatitis B antigen, and that the combination of CEL-1000 with MAS-1, a proprietary water-in-oil adjuvant delivery system owned by Mercia Pharma, induced high...

Cethromycin Shown Effective Against Anthrax in Study

Advanced Life Sciences Achieves Key Endpoint in Primate Study CHICAGO, May 02, 2007 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. today announced that its novel respiratory antibiotic, Cethromycin, was shown to be effective in preventing inhalation anthrax infection. This conclus...

RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer

IRVING, Texas--(BUSINESS WIRE)--May 15, 2007 - Reata Pharmaceuticals, Inc. today announced the publication of an article in the May 2007 issue of the journal Cancer Research showing that RTA 402, the company's Phase 2 development candidate for cancer, was highly effective in a rigorous animal model...

Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma

Adding MabThera to first line chemotherapy significantly increases patients_ overall survival BASEL, Switzerland (21 May, 2007) _ In a study published yesterday in the Journal of Clinical Oncology, MabThera (rituximab) plus chemotherapy (MCP*) was shown to significantly improve survival in patie...

Efficacy and Safety Profile of Basilea's Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress

BASEL, Switzerland, May 21, 2007 - Results from phase III clinical trials and further human pharmacology studies were presented at the 16th Congress of the European Academy of Dermatology and Venereology (EADV). These data highlighted the efficacy and safety profile of alitretinoin as a potential ...

CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals

VIENNA, Va., May 23, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announces that CEL-1000 increased the immune response against H5 avian influenza antigen in combination with MAS-1, a water-in-oil adjuvant delivery system. These findings were presented on May 23, 2007 by Dr. Daniel Zimmerman...

Gabapentin Shown Effective for Fibromyalgia Pain

BETHESDA, Md., June 11, 2007--New research supported by the National Institutes of Healths National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) shows that the anticonvulsant medication gabapentin , which is used for certain types of seizures, can be an effective t...

RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments

IRVING, Texas--(BUSINESS WIRE)--Jun 29, 2007 - Reata Pharmaceuticals, Inc. today announced the presentation of new preclinical data showing their lead anti-cancer agent, the Synthetic Triterpenoid RTA 402, is effective at protecting against common toxicities caused by traditional cancer treatments....

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...val. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Vectibix. Vectibix has not shown a treatment benefit for patients whose tumors had KRAS mutations in codon 12 or 13. In December 2007, the EMEA granted a conditional marketin...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's technology has been shown to increase oral bioavailability and inhibit penetration across the blood-brain barrier, an important potential advance for small molecule therapies. ...

ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer

...anitumumab) and Erbitux (cetuximab). On July 17, 2009, the FDA noted that, "retrospective analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Erbitux/Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13," and that the use of the drugs is not recomm...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

...activator of AMPK (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases. Activation of AMPK has been shown to lower fasting blood glucose levels and improve glucose disposal following a glucose challenge, two key goals in the management of type 2 diabetes. ...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...erase P1-1 which in turn facilitates the activation of JNK kinase, a key regulator of cellular growth and differentiation of blood. TELINTRA has been shown to stimulate normal multilineage differentiation of blood stem cell precursors and induce cancer cell death in human leukemia cell lines. Additional ...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

...oLindac , a novel DACH platinum drug that has shown to be active in many solid tumors in human clinica... ProLindac is a novel DACH platinum drug that has shown to be active in many solid tumors in human clinica...ac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in ...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

...e potent than Pharmasset's first generation nucleoside polymerase inhibitor, RG7128 (formerly known as R7128). In vitro studies of PSI-7851 have not shown evidence of any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. Like RG7128, PSI-7851 has demonstrated...

Is Your Hair Taking a Break?

...he U.S. Food and Drug Administration (FDA) for female-pattern hair loss. Minoxidil 5% is only FDA-approved for male-pattern hair loss, but it has been shown to be very effective in women as well. Both the 2% and 5% solutions are available over-the-counter. While minoxidil does not grow new hair, it works b...

Diabetes Gene Raises Odds of Lower Birth Weight

... PHILADELPHIA, July 29 /PRNewswire-USNewswire/ -- Pediatric researchers have found that a gene previously shown to be involved in the development of type 2 diabetes also predisposes children to having a lower birth weight. The finding sheds light on a possible g...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...ils below). "Our objective with R788 in RA is to position the product after methotrexate and before biological therapies are used. We have shown excellent results in that patient population in our earlier TASKi1 and TASKi2 studies, and we believe that patient population represents the large mar...

July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals

...aken only under a doctor's supervision. Vitamin C: Studies have shown that eating food high in vitamin C can lower rates of cancer and heart dise...her vitamin C supplements provide the same benefits. Studies have shown that vitamin C supplements, taken with some other antioxidants and zinc, ma...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

... glutathione levels, a hallmark of drug-resistant tumors. Brostallicin was shown to affect DNA in both dividing and quiescent cells. Its actions can be foll...stallicin, a novel synthetic second-generation DNA minor groove binder, has shown potent cancer killing activity, and has demonstrated synergism in combinati...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

...ir and cell proliferation. By inhibiting the enzymatic activity of PARP, BSI-201 significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors. "We are extremely pleased to be launching the Phase 3 clinical trial so ...

New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed

...se in combination with other antiretroviral agents for the treatment of HIV infection. VIRAMUNE does not cure HIV or AIDS, and has not been shown to reduce the risk of passing HIV to others through sexual contact or blood contamination. VIRAMUNE can cause severe liver disease and skin ...

Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364

...ified form of the synthetic guanylhydrozone, semapimod. Semapimod has been shown to inhibit the signal transduction pathways that lead to the production of ... led to human clinical trials. An intravenous formulation of semapimod was shown to have significant anti-inflammatory activity in Phase II clinical trials ...

Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results

... 90 clinical sites in 13 countries, primarily in Asia, South America and Eastern Europe, were enrolled in the trial. "This is the first drug shown to be effective in ameliorating the signs and symptoms of lupus in decades," said Daniel J. Wallace, MD, clinical professor of medicine at the David G...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...eek 52. A clinically and statistically significant improvement was shown in patient response rate for belimumab plus standard of care, vs. ... patient response rate were consistent with the overall improvement shown for the primary endpoint. -- Results for prespecified major s...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

...l immunogenicity studies of its H1N1 (swine) influenza vaccine and will manufacture clinical trial material by the end of the month. This vaccine has shown good production yields as well as excellent immunogenicity, even after just a single inoculation. "Our vaccine platform provides several pote...

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

... spread of influenza within a host. Peramivir has demonstrated clinical activity and safety in prior human studies. In laboratory tests, peramivir has shown activity against various viral strains, including the novel influenza A (H1N1) virus. In the U.S., BioCryst is preparing plans for additional Phase 3...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

...alth and Human Services guidelines for antiretroviral therapy. Additionally, like vicriviroc, it is administered as a once daily dose and it has been shown to have a more favorable lipid safety profile than other drugs in the PI class. The study is being sponsored by Schering-Plough with suppor...

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

... SAN DIEGO and ANN ARBOR, Mich., July 13 /PRNewswire-FirstCall/ -- Results from a study published by the University of Michigan have shown that as many as 15% of women in the study group determined to be negative for the presence of human papillomavirus (HPV) in the cervix, via the most c...
Other Tags
(Date:2/5/2015)... MOUNTAIN VIEW, Calif. , Feb. 3, 2015 ... screen printer technology, demand from industries such as ... the global market for surface mount technology (SMT) ... manual equipment to automatic control will push the ... glue dispensers will remain steady as glue dispensers ...
(Date:1/22/2015)... Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of ... of its new website design. "When we launched ... says Peter O,Neill , founder and CEO of FindBiometrics. ... needs involvement from the key players on a very broad ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a leader ... announced the launch of a TR-FRET (time resolved ... Transcreener UDP Assay, a high throughput screening assay ... assay will allow for sensitive detection of hundreds ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
(Date:3/6/2015)... 06, 2015 First Choice Emergency Room ... new facility is located at 13351 W. Bowles Avenue, Littleton, ... team is ready 24-7 to provide the highest quality emergency ... Medical Director of First Choice Emergency Room Littleton. ... the South Metro Denver Chamber of Commerce and a medical ...
(Date:3/6/2015)... Magellan Rx Management’s 2014 Medical Pharmacy ... key trends and statistics on one of the nation’s ... Magellan Rx Management will discuss key findings from the ... Specialty Drug Spend,” a complimentary March 19 webinar, managed ... drug spend makes up more than a quarter of ...
(Date:3/6/2015)... In a new study conducted at a Warsaw hospital, ... pain was their first mesothelioma symptom. Surviving Mesothelioma has just ... to read it now. , Doctors at the Central ... mesothelioma patients between 2006 and 2012 and found ... that first prompted them to see a doctor. For some, ...
(Date:3/6/2015)... You Wealth Revolution ( http://www.youwealthrevolution.com/info ... ‘energy’ experiment to determine if quick remote meditations ... quick ‘5 -7 minute’ remote energy and consciousness ... their life improving - often times very quickly. ... According to research, respondents saw the following common ...
(Date:3/6/2015)... March 06, 2015 The producers of ... air dates for Spokane, Washington and vicinity. This is a ... shop and dine, and many outdoor activities. It is also ... local economy. Six major hospitals call the city home and ... border. The medically-focused cable TV program will be broadcast on ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:The Health Briefs TV Show to Air in Spokane, Washington 2
Other Contents